Shattuck Labs (STTK) Profit After Tax (2019 - 2026)
Shattuck Labs (STTK) posted quarterly Profit After Tax of -$14.8 million for Q1 2026, down 7.8% year-over-year from -$16.0 million in Q1 2025, and down 17.34% quarter-over-quarter from -$12.6 million in Q4 2025.
Shattuck Labs (STTK) Profit After Tax (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported Profit After Tax for 8 consecutive years, with -$14.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 7.8% year-over-year to -$14.8 million; the TTM figure through Mar 2026 stood at -$49.9 million (up 29.36% YoY), while the FY2025 annual figure was -$48.8 million, up 35.28% from the prior year.
- Profit After Tax slipped to -$14.8 million in Q1 2026 per STTK's latest filing, from -$12.6 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$10.1 million in Q3 2025 and bottomed at -$27.5 million in Q3 2023.
- Historically, Profit After Tax has averaged -$19.3 million across 5 years, with a median of -$18.7 million in 2024.
- Annual changes were most pronounced in 2022 — Profit After Tax tumbled 364.39% — and 2025, when it jumped 42.2%.
- Shattuck Labs' Profit After Tax stood at -$25.4 million in 2022, then soared by 30.38% to -$17.7 million in 2023, then slipped by 5.59% to -$18.7 million in 2024, then soared by 32.6% to -$12.6 million in 2025, then slipped by 17.34% to -$14.8 million in 2026.
- Business Quant data shows STTK's Profit After Tax at -$14.8 million in Q1 2026, -$12.6 million in Q4 2025, and -$10.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Shattuck Labs | 962.96 Mn | 962.96 Mn | - | -15.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.22 Mn |
| Mar 31, 2026 | -14.77 Mn |
| Dec 31, 2025 | -12.59 Mn |
| Sep 30, 2025 | -10.06 Mn |
| Jun 30, 2025 | -12.46 Mn |
| Mar 31, 2025 | -13.70 Mn |
| Dec 31, 2024 | -18.68 Mn |
| Sep 30, 2024 | -16.68 Mn |
| Jun 30, 2024 | -21.55 Mn |
| Mar 31, 2024 | -18.50 Mn |
| Dec 31, 2023 | -17.69 Mn |
| Sep 30, 2023 | -27.54 Mn |
| Jun 30, 2023 | -21.35 Mn |
| Mar 31, 2023 | -20.72 Mn |
| Dec 31, 2022 | -25.41 Mn |
| Sep 30, 2022 | -24.86 Mn |
| Jun 30, 2022 | -27.37 Mn |
| Mar 31, 2022 | -24.53 Mn |
| Dec 31, 2021 | 9.61 Mn |
| Sep 30, 2021 | -17.41 Mn |